CpG and Non-CpG Oligodeoxynucleotides Induce Differential Proinflammatory Gene Expression Profiles in Liver and Peripheral Blood Leukocytes in Mice

REFERENCES

• Aderem A., Ulevitch R. J. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782–787, [CSA]
   PubMed Web of Science ®Google Scholar
• Agrawal S. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim. Biophys. Acta 1999; 1489: 53–68, [CSA]
   PubMed Web of Science ®Google Scholar
• Asselin-Paturel C., Boonstra A., Dalod M., Durand I., Yessaad N., Dezutter-Dambuyant C., Vicari A., O'Garra A., Biron C., Briere F., Trinchieri G. Mouse Type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat. Immunol. 2001; 2: 1144–1150, [CSA]
   PubMed Web of Science ®Google Scholar
• Barish C. F. Alicaforsen therapy in inflammatory bowel disease. Expert Opin. Biol. Ther. 2005; 5: 1387–1391, [CSA]
   PubMed Web of Science ®Google Scholar
• Cichy J., Pure E. The liberation of CD44. J. Cell Biol. 2003; 161: 839–843, [CSA]
   PubMed Web of Science ®Google Scholar
• Condon T. P., Flournoy S., Sawyer G. J., Baker B. F., Kishimoto T. K., Bennett C. F. ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes. Antisense Nucl. Acid Drug Dev. 2001; 11: 107–116, [CSA]
   PubMedGoogle Scholar
• el-Gabalawy H., Canvin J., Ma G. M., Van der Vieren M., Hoffman P., Gallatin M., Wilkins J. Synovial distribution of alpha d/CD18, a novel leukointegrin. Comparison with other integrins and their ligands. Arthritis Rheum. 1996; 39: 1913–1921, [CSA]
   PubMed Web of Science ®Google Scholar
• Hartmann G., Weiner G. J., Krieg A. M. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 1999; 96: 9305–9310, [CSA]
   PubMed Web of Science ®Google Scholar
• Henry S. P., Bolte H., Auletta C., Kornbrust D. J. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology 1997a; 120: 145–155, [CSA]
   PubMed Web of Science ®Google Scholar
• Henry S. P., Grillone L. R., Orr J. L., Brunner R. H., Kornbrust J., Kornbrust D. J. Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague–Dawley rats. Toxicology 1997b; 116: 77–88, [CSA]
   PubMed Web of Science ®Google Scholar
• Henry S. P., Stecker K., Brooks D., Monteith D., Conklin B., Bennett C. F. Chemically-modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther. 2000; 292: 468–479, [CSA]
   PubMed Web of Science ®Google Scholar
• Henry S. P., Taylor J., Midgley L., Levin A. A., Kornbrust D. J. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice. Antisense Nucl. Acid Drug Dev. 1997c; 7: 473–481, [CSA]
   PubMedGoogle Scholar
• Henry S. P., Templin M. V., Gillett N., Rojko J., Levin A. A. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Toxicol. Pathol. 1999; 27: 95–100, [CSA]
   PubMed Web of Science ®Google Scholar
• Hoke G. D., Draper K., Freier S., Gonzalez C., Driver V. B., Zounes M. C., Ecker D. J. Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucl. Acids Res. 1991; 19: 5743–5748, [CSA]
   PubMed Web of Science ®Google Scholar
• Imler J. L., Hoffmann J. A. Toll receptors in innate immunity. Trends Cell Biol. 2001; 11: 304–311, [CSA]
   PubMed Web of Science ®Google Scholar
• Jakob T., Walker P. S., Krieg A. M., Udey M. C., Vogel J. C. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of TH1 responses by immunostimulatory DNA. J. Immunol. 1998; 161: 3042–3049, [CSA]
   PubMed Web of Science ®Google Scholar
• Janatpour M. J., Hudak S., Sathe M., Sedgwick J. D., McEvoy L. M. Tumor necrosis factor-dependent segmental control of MIG expression by high endothelial venules in inflamed lymph nodes regulates monocyte recruitment. J. Exp. Med. 2001; 194: 1375–1384, [CSA]
   PubMed Web of Science ®Google Scholar
• Jiang G., Li Z., Liu F., Ellsworth K., Dallas-Yang Q., Wu M., Ronan J., Esau C., Murphy C., Szalkowski D., Bergeron R., Doebber T., Zhang B. B. Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J. Clin. Invest. 2005; 115: 1030–1038, [CSA]
   PubMed Web of Science ®Google Scholar
• Jinquan T., Quan S., Jacobi H. H., Jing C., Millner A., Jensen B., Madsen H., Ryder L. P., Svejgaard A., Malling H. J., Skov P. S., Poulsen L. K. CXC chemokine receptor 3 expression on CD34(+) hematopoietic progenitors from human cord blood induced by granulocyte-macrophage colony-stimulating factor: Chemotaxis and adhesion induced by its ligands, interferon gamma-inducible protein 10 and monokine induced by interferon gamma. Blood 2000; 96: 1230–1238, [CSA]
   PubMedGoogle Scholar
• Kandimalla E. R., Bhagat L., Zhu F., Yu D., Cong Y., Wang D., Tang J. X., Tang J., Knetter C. F., Lien E., Agrawal S. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc. Natl. Acad. Sci. USA 2003; 100: 14303–14308, [CSA]
   PubMed Web of Science ®Google Scholar
• Kansas G. S., Muirhead M. J., Dailey M. O. Expression of the CD11/CD18, leukocyte adhesion molecule 1, and CD44 adhesion molecules during normal myeloid and erythroid differentiation in humans. Blood 1990; 76: 2483–2492, [CSA]
   PubMed Web of Science ®Google Scholar
• Klinman D. M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 2004; 4: 249–258, [CSA]
   PubMed Web of Science ®Google Scholar
• Krieg A. M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002; 20: 709–760, [CSA]
   PubMed Web of Science ®Google Scholar
• Krieg A. M., Yi A., Matson S., Waldschmidt T. J., Bishop G. A., Teasdale R., Koretzky G. A., Klinman D. M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546–549, [CSA]
   PubMed Web of Science ®Google Scholar
• Lalor P. F., Shields P., Grant A., Adams D. H. Recruitment of lymphocytes to the human liver. Immunol. Cell. Biol. 2002; 80: 52–64, [CSA]
   PubMedGoogle Scholar
• Levin A. A. A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1999; 1489: 69–84, [CSA]
   PubMed Web of Science ®Google Scholar
• Levin A. A., Henry S. P., Monteith D., Templin M. Toxicity of Antisense Oligonucleotides. Antisense Drug Technology, S. T. Crooke. Marcel Dekker, Inc., New York 2001
   Google Scholar
• Levin A. A., Monteith D. K., Leeds J. M., Nicklin P. L., Geary R. S., Butler M., Templin M. V., Henry S. P. Toxicity of oligodeoxynucleotide therapeutic agents. Antisense Research and Application, S. T. Crooke. Springer, Heidelberg 1998
   Google Scholar
• Lipford G. B., Sparwasser T., Bauer M., Zimmermann S., Koch E., Heeg K., Wagner H. Immunostimulatory DNA: Sequence-dependent production of potentially harmful or useful cytokines. Eur. J. Immunol. 1997; 27: 3420–3426, [CSA]
   PubMed Web of Science ®Google Scholar
• McQueen C. A., Rosado R. R., Williams G. M. Effect of nalidixic acid on DNA repair in rat hepatocytes. Cell Biol. Toxicol. 1989; 5: 201–206, [CSA]
   PubMedGoogle Scholar
• Muller W. A. New mechanisms and pathways for monocyte recruitment. J. Exp. Med. 2001; 194: F47–51, [CSA]
   Google Scholar
• Nakano H., Yanagita M., Gunn M. D. CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J. Exp. Med. 2001; 194: 1171–1178, [CSA]
   PubMed Web of Science ®Google Scholar
• Peng S. L. Signaling in B-cells via Toll-like receptors. Curr. Opin. Immunol. 2005; 17: 230–236, [CSA]
   PubMedGoogle Scholar
• Pisetsky D. S., Reich C. F. The influence of base sequence on the immunological properties of defined oligonucleotides. Immunopharmacology 1998; 40: 199–208, 3rd.[CSA]
   PubMedGoogle Scholar
• Scheule R. K. The role of CpG motifs in immunostimulation and gene therapy. Adv. Drug Delivery Rev. 2000; 44: 119–134, [CSA]
   PubMed Web of Science ®Google Scholar
• Schnare M., Holt A. C., Takeda K., Akira S., Medzhitov R. Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. Curr. Biol. 2000; 10: 1139–1142, [CSA]
   PubMed Web of Science ®Google Scholar
• Senn J. J., Burel S., Henry S. P. Non-CpG-containing antisense 2′ MOE oligonucleotides activate a proinflammatory response independent of TLR-9 or MyD88. J. Pharmacol. Exp. Ther. 2005; 314: 972–979, [CSA]
   PubMed Web of Science ®Google Scholar
• Short M. L., Nickel J., Schmitz A., Renkawitz R. Lysozyme gene expression and regulation. Cell Growth Differ. 1996; 75: 243–257, [CSA]
   Google Scholar
• Tan J., Quan S., Jacobi H. H., Jing C., Millner A., Jensen B., Madsen H. O., Ryder L. P., Svejgaard A., Malling H. J., Skov P. S., Poulsen L. K. CXC chemokine receptor 3 expression on CD34(+) hematopoietic progenitors from human cord blood induced by granulocyte-macrophage colony-stimulating factor: Chemotaxis and adhesion induced by its ligands, interferon gamma-inducible protein 10 and monokine induced by interferon gamma. Blood 2000; 96: 1230–1238, [CSA]
   PubMedGoogle Scholar
• Uhlmann E., Vollmer J. Recent advances in the development of immunostimulatory oligonucleotides. Curr. Opin. Drug Discov. Devel. 2003; 6: 204–217, [CSA]
   PubMed Web of Science ®Google Scholar
• Ulbrich H., Eriksson E. E., Lindbom L. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol. Sci. 2003; 24: 640–647, [CSA]
   PubMed Web of Science ®Google Scholar
• Wagner H. Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr. Opin. Microbiol. 2002; 5: 62–69, [CSA]
   PubMed Web of Science ®Google Scholar
• Wang H., Rayburn E., Zhang R., Zhang R. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics. Curr. Pharm. Des. 2005; 11: 2889–2907, [CSA]
   PubMed Web of Science ®Google Scholar
• Wild J. S., Sur S. CpG oligonucleotide modulation of allergic inflammation. Allergy 2001; 56: 365–376, [CSA]
   PubMedGoogle Scholar
• Zhang Y., Shoda L. K., Brayton K. A., Estes D. M., Palmer G. H., Brown W. C. Induction of interleukin-6 and interleukin-12 in bovine B-lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif. J. Interferon Cytokine Res. 2001; 21: 871–81, [CSA]
   PubMedGoogle Scholar
• Zhao Q., Temsamani J., Zhou R., Agrawal S. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucl. Acid Drug Dev. 1997; 7: 495–502, [CSA]
   PubMedGoogle Scholar